Children with intermittent asthma flare-ups associated with infection may benefit from taking Singulair (montelukast) to reduce their asthma symptoms. Of the approximately 550 children with intermittent asthma between the ages of 2 and 5 years, 278 participants were given Singulair for 12 months. The participants were given the standard dose of either 4 mg or 5 mg, depending on their age. The remaining participants were given a placebo.
The results of the study showed that the participants taking Singulair had 31.9% fewer asthma exacerbations and 31.6% fewer asthma episodes. The participants receiving the medication needed to take inhaled corticosteroids 40% less, compared with children on placebo. The frequency of oral corticosteroid use was lowered by 17.5% in the oral asthma drug group, compared with the placebo group.
One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.
Clinical features with downloadable PDFs